Search clinical trials for: Dapagliflozin matching placebo

Total 55178 results

Kiniksa Pharmaceuticals, Ltd.

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

Healthy Volunteers

Australia, United States
Boehringer Ingelheim

Withdrawn

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

Asthma
Addex Pharma S.A.

Completed

ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)

Gastroesophageal Reflux

United States, France, Germany, Netherlands, Switzerland
Takeda

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Coronavirus Disease
University of Rochester
AstraZeneca

Completed

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation (DAPA-AF)

Atrial Fibrillation

United States
Mansoura University

Active, not recruiting

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

Lupus Nephritis | BMD | SGLT2 INHIBITORS

Egypt
AstraZeneca
Parexel; PRA Health Sciences; Q2 Solutions; Covance Laboratories, Inc

Completed

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Type 2 Diabetes

United States, Israel, Hungary, Russian Federation, Mexico, Romania, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
The University of Texas Health Science Center at...
Janssen Scientific Affairs, LLC

Withdrawn

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Cardiovascular Diseases | Type2 Diabetes Mellitus

United States
LM Diagnósticos S.L.
AstraZeneca

Unknown

Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

Type2 Diabetes

Spain
University of Colorado, Denver

Recruiting

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

Vascular Diseases | Diabetes | Kidney Transplant; Complications

United States
University of Oklahoma

Recruiting

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

Diabetes Mellitus | Atrial Fibrillation

United States
Andrea Giaccari

Recruiting

Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity (DapaHeart)

Type2 Diabetes Mellitus | Stable Coronary Artery Disease

Italy
University of Pennsylvania
Amgen

Completed

Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

HFrEF

United States
Mansoura University

Completed

Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Acute Heart Failure

Egypt
Yonsei University

Completed

Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Korea, Republic of
AstraZeneca
Bristol-Myers Squibb

Completed

Phase III Insulin Add-On Asia Regional Program - ST

Diabetes

China, Korea, Republic of, Singapore
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
University Medical Center Groningen
AstraZeneca

Enrolling by invitation

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria (ZODIAC)

Chronic Kidney Diseases

Netherlands, Canada, United States, Denmark, United Kingdom
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Completed

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, France, Spain, Ireland, Australia, Puerto Rico, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Actinogen Medical
ICON plc

Completed

Xanamem™ in Healthy Elderly Subjects (XanaHES)

Cognitive Function | Peripheral Neuropathy | Electrocardiography | Central Nervous System | Safety | Healthy Ageing | Cortisol | Cerebrospinal Fluid | Small Fibre Neuropathy

Australia
October 6 University
Cairo University; National Heart Institute, Egypt

Recruiting

Canagliflozin in Patients With Acute Decompansted Heart Failure (The CANA -AHF)

Diabetes Mellitus | Chronic Heart Failure | Acute Heart Failure

Egypt
Merit E. Cudkowicz, MD
Denali Therapeutics Inc.

Enrolling by invitation

HEALEY ALS Platform Trial - Regimen G DNL343

Amyotrophic Lateral Sclerosis

United States
CuraSen Therapeutics, Inc.

Withdrawn

A Study of CST-2032 in Subjects With Cognitive Impairment

Mild Cognitive Impairment (MCI) | Parkinson Disease (PD)
National Health Research Institutes, Taiwan

Completed

A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects

Diabetes Mellitus, Type 2

Taiwan
Crucell Holland BV

Completed

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

Rabies

United States
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Type 1 Diabetes | Type 2 Diabetes

United States
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
Albina Nowak, MD

Not yet recruiting

Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

Fabry Disease
Tor Biering-Sørensen

Recruiting

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients With CKD (DECODE-CKD)

Chronic Kidney Diseases

Denmark
Mario Negri Institute for Pharmacological Research
AstraZeneca

Completed

Dapagliflozin in Non-diabetic Stage IV CKD (ADAPT)

Chronic Kidney Diseases

Italy
University Medical Center Groningen
AstraZeneca

Terminated

TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension (TIMOTHY)

Albuminuria

Netherlands
AstraZeneca

Completed

A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients (DAPACARD)

Diabetes Mellitus Type 2

Finland, Sweden
Kinderkrankenhaus auf der Bult

Completed

Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes (DAPA-IIT1)

Type 1 Diabetes

Germany
Nobelpharma

Completed

Efficacy Confirmation Study of NPC-09

GNE Myopathy | Nonaka Disease | Distal Myopathy With Rimmed Vacuoles (DMRV) | Hereditary Inclusion Body Myopathy (hIBM)

Japan
Centre Hospitalier Universitaire Dijon
Novartis Pharmaceuticals

Recruiting

Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP) (SESAM)

Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)

France
Regeneron Pharmaceuticals

Recruiting

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

Heart Failure

Turkey, Moldova, Republic of, Hungary, Belgium, Poland, Romania
Regeneron Pharmaceuticals

Active, not recruiting

A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants

Healthy Volunteers

New Zealand
Merit E. Cudkowicz, MD
Prilenia Therapeutics

Completed

HEALEY ALS Platform Trial - Regimen D Pridopidine

Amyotrophic Lateral Sclerosis

United States
Guangdong Hengrui Pharmaceutical Co., Ltd

Enrolling by invitation

A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough

Refractory Chronic Cough

China
GlaxoSmithKline

Completed

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects

Hepatitis B

United Kingdom
AstraZeneca
Parexel; George Clinical Pty Ltd

Terminated

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Chronic Kidney Disease

United States, Taiwan, Germany, Hungary, Malaysia, Japan, Israel, Poland, Brazil, Ukraine, Argentina
Hospital General Universitario Gregorio Marañon
Instituto de Salud Carlos III; University of Navarra; Fundación para la Investigación...

Unknown

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF (CARDIA-STIFF)

Diabetes Mellitus, Type 2 | Heart Failure With Preserved Ejection Fraction

Spain
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of Dapagliflozin Taken Twice-daily

Type 2 Diabetes

South Africa, Germany, Hungary, Romania, Slovakia, Switzerland, Ukraine
Boehringer Ingelheim

Withdrawn

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids

Asthma
Hilda Elizabeth Macías Cervantes

Completed

Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography

Myocardial Infarction | Diabetes Mellitus, Type 2 | Unstable Angina | Diabete Type 2

Mexico
Hospital de Clinicas de Porto Alegre
Vifor Pharma

Not yet recruiting

IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency (COMBINED-HF)

Heart Failure, Systolic | Iron Deficiencies

Brazil

Search clinical trials for: Dapagliflozin matching placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations